


AZD8931 diFuMaric acid

Chemical Properties

CAS No. :	1196531-39-1
Formula:	C ₃₁ H ₃₃ ClFN ₅ O ₁₁
Molecular Weight:	706.1
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC ₅₀ of 4 nM, 3 nM and 4 nM, respectively).
Targets(IC ₅₀)	EGFR
In vivo	AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro. AZD8931 monotherapy inhibited xenograft growth[1].
Animal Research	Two IBC cell lines SUM149 and FC-IBC-02. Cell growth and apoptotic cell death were examined in vitro. For the in vivo tumor growth studies, IBC cells were orthotopically transplanted into the mammary fat pads of immunodeficient mice. AZD8931 was given by daily oral gavage at doses of 25 mg/kg, 5 days/week for 4 weeks. Paclitaxel was subcutaneously injected twice weekly[1].

Solubility Information

Solubility	DMSO: 30 mg/mL (42.49 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.4162 mL	7.0811 mL	14.1623 mL
5 mM	0.2832 mL	1.4162 mL	2.8325 mL
10 mM	0.1416 mL	0.7081 mL	1.4162 mL
50 mM	0.0283 mL	0.1416 mL	0.2832 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zhaomei Mu, Teresa Klinowska, Xiaoshen Dong, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. *J Exp Clin Cancer Res.* 2014 May 30;33(1):47.

Morrison G, Fu X, Shea M, et al. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. *Breast Cancer Res Treat.* 2014, 144(2):263-272.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481